A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus.

Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEGIN
  • Sponsors Genentech
  • Most Recent Events

    • 26 Jun 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 09 Mar 2010 Trial has been halted since May 2008 due to serious and opportunistic infections signals, as reported by media releases from Roche and Biogen Idec.
    • 09 Mar 2010 Trial has been halted since May 2008 due to serious and opportunistic infections signals, as reported by media releases from Roche and Biogen Idec.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top